↓ Skip to main content

Cannabinoids for Tourette's Syndrome

Overview of attention for article published in Cochrane database of systematic reviews, October 2009
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (98th percentile)
  • High Attention Score compared to outputs of the same age and source (95th percentile)

Citations

dimensions_citation
85 Dimensions

Readers on

mendeley
164 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Cannabinoids for Tourette's Syndrome
Published in
Cochrane database of systematic reviews, October 2009
DOI 10.1002/14651858.cd006565.pub2
Pubmed ID
Authors

Adrienne Curtis, Carl E Clarke, Hugh E Rickards

Abstract

Gilles de la Tourette Syndrome (GTS) is a developmental neuropsychiatric disorder characterised by the presence of chronic motor and phonic tics. Drugs currently used in the treatment of GTS either lack efficacy or are associated with intolerable side effects. There is some anecdotal and experimental evidence that cannabinoids may be effective in treating tics and compulsive behaviour in patients with GTS. There are currently no systematic Cochrane reviews of treatments used in GTS. There is one other Cochrane review being undertaken at present, on the use of fluoxetine for tics in GTS.

X Demographics

X Demographics

The data shown below were collected from the profiles of 9 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 164 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 <1%
Unknown 163 99%

Demographic breakdown

Readers by professional status Count As %
Researcher 26 16%
Student > Ph. D. Student 18 11%
Student > Postgraduate 13 8%
Student > Master 12 7%
Student > Bachelor 11 7%
Other 31 19%
Unknown 53 32%
Readers by discipline Count As %
Medicine and Dentistry 51 31%
Psychology 14 9%
Biochemistry, Genetics and Molecular Biology 8 5%
Pharmacology, Toxicology and Pharmaceutical Science 8 5%
Agricultural and Biological Sciences 5 3%
Other 21 13%
Unknown 57 35%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 61. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 20 June 2022.
All research outputs
#704,595
of 25,542,788 outputs
Outputs from Cochrane database of systematic reviews
#1,316
of 13,151 outputs
Outputs of similar age
#1,686
of 107,165 outputs
Outputs of similar age from Cochrane database of systematic reviews
#4
of 85 outputs
Altmetric has tracked 25,542,788 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 13,151 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 35.7. This one has done well, scoring higher than 89% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 107,165 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 98% of its contemporaries.
We're also able to compare this research output to 85 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 95% of its contemporaries.